DCAT Value Chain Insights

July 5, 2016

By Patricia Van Arnum

Given the high cost of new drug development, pharmaceutical companies, researchers, and other organizations are looking for innovative ways to reduce time and costs. Drug repurposing and repositioning hold some answers.

Companies, such as Sanofi and Astellas Pharma, have recently announced external partnerships and increased internal focus on drug repurposing and repositioning. Drug repurposing refers to studying drugs that are already approved to treat one disease or condition to see if they are safe and effective for treating other diseases. Drug repositioning refers to taking a pharma pipeline compound already shown to be safe for human use and finding new indications that can be studied to expand a compound’s value. Industry estimates place the market for repurposed drugs at $24.4 billion in 2015 with projections that it could reach $31.3 billion in 2020. So how are pharmaceutical companies, researchers, and other organizations responding? DCAT Value Chain Insights (VCI) examines recent developments.

Click here to read full article

Click here to sign up for our eNewsletter today!

Please include your Full Name* and Email Address*


If the link above doesn't work, please contact our Admin support at admin@cureswithinreach.org with your Full Name and Email Address to sign up!


Cures Within Reach

134 N. LaSalle, #1130
Chicago, IL 60602


All funds donated to Cures Within Reach may be tax deductible for federal income tax purposes. 

Partnership for Cures DBA Cures Within Reach is recognized by the IRS as a 501(c)3 tax-exempt not-for-profit organization, tax ID 20-3620169.


Saturday the 28th. Copyright 2018 Cures Within Reach.